Mesenchymal Stem Cell Committee

Charter

The Mesenchymal Stem Cell Committee strives to:

  • Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the non-hematopoietic stem cell field.
  • Review the status of the MSC field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing MSCs.
  • Foster international discussion about controversies in the MSC field and method standardization.
  • Publish position papers and engage in scientific discourse as necessary to advance the field.

Projects and Objectives

  • Publish a sequence of MSC review papers in Cytotherapy on immunotherapy, controversies and safety.
  • Plan and develop position papers on MSC clinical trial design for publication in 2014.
  • Organize international expert panels to openly discuss controversies in the MSC field and drive consensus on scientific and technical principles.
  • Contribute to the ISCT Annual Meeting program.

Publications

Martin I, De Boer J, Sensebé L; MSC Committee of the International Society for Cellular Therapy. A relativity concept in mesenchymal stromal cell manufacturing. Cytotherapy. 2016 May;18(5):613-20. doi: 10.1016/j.jcyt.2016.02.004. Review. PubMed PMID: 27059199.

Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016 Feb;18(2):151-9.  doi: 10.1016/j.jcyt.2015.11.008. PubMed PMID: 26724220; PubMed Central PMCID: PMC4745114.

Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013 Sep;15(9):1054-61. doi: 10.1016/j.jcyt.2013.02.010. PubMed PMID: 23602578.

Phinney DG, Galipeau J, Krampera M, Martin I, Shi Y, Sensebe L. MSCs: science and trials. Nat Med. 2013 Jul;19(7):812. doi: 10.1038/nm.3220. PubMed PMID: 23836216.

Phinney DG, Sensebé L. Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy. 2013 Feb;15(2):140-5. doi: 10.1016/j.jcyt.2012.11.005. Review. PubMed PMID: 23321325.

Sensebé L, Tarte K, Galipeau J, Krampera M, Martin I, Phinney DG, Shi Y; MSC Committee of the International Society for Cellular Therapy. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell. 2012 Jan 6;10(1):9-10; author reply 10-1. doi: 10.1016/j.stem.2011.12.005.  PubMed PMID: 22226349.

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement (Cytotherapy 2006, 8(4): 315-317)



 Committee Members:



 

Jacques Galipeau, MD
University of Wisconsin-Madison
Madison, WI, United States

 Mauro Krampera, MD
University of Verona
Verona, Italy
Katarina Le Blanc, MD, PhD
Karolinska University Hospital
Stockholm, Sweden
Ivan Martin, PhD
University Hospital Basel
Basel, Switzerland
Don Phinney, PhD
Scripps Florida
Jupiter, FL, United States
Yufang Shi, PhD
Shanghai Institutes for Biological Sciences
Shanghai, China
Luc Sensebé, MD, PhD
Etablissement Francais Du Sang EFS
Toulouse, France


© 2015 International Society for Cellular Therapy. All rights reserved.
ISCT, International Society for Cellular Therapy, and the ISCT logo are registered service marks of The International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of The International Society for Cellular Therapy.